Arcutis Biotherapeutics logo
Arcutis Biotherapeutics
ARQT | NASDAQ
Chart Builder DCF Calculator
$27.15
-$1.11 (-3.93%)
At close: Nov 16, 2026, 4:00 PM ET
$25.79
-$1.36 (-5.01%)
After-hours: Nov 16, 2026, 7:32 PM ET

Arcutis Biotherapeutics Company Profile

Company profile explained

Company Profile

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.

Key Executives

Name Position
Todd Franklin Watanabe President, Chief Executive Officer & Director
Latha Vairavan Senior Vice President & Chief Financial Officer
Masaru Matsuda Executive VP, Chief Legal Officer & Corporate Secretary
Aleen Hosdaghian Vice President of Marketing
Amanda Sheldon Head of Corporate Communications
Bhaskar Chaudhuri Co-Founder & Director Emeritus
Brian Schoelkopf Head of Investor Relations
Patrick E. Burnett Executive Vice President & Chief Medical Officer
Steve Arias Vice President of Compliance & Privacy
Todd Tucker Senior Vice President & Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Oct 28, 2026 3 Filing
Oct 28, 2026 4 Filing
Oct 28, 2026 8-K Current Report
Oct 19, 2026 4 Filing
Oct 05, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 18, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 10, 2026 4 Filing
Aug 28, 2026 4 Filing
Aug 24, 2026 4 Filing
View All SEC Filings ➞
Arcutis Biotherapeutics
Arcutis Biotherapeutics logo
Country United States
IPO Date Jan 31, 2020
Industry Biotechnology
Sector Healthcare
Employees 354
CEO Todd Franklin Watanabe

Contact Details

3027 Townsgate Road Westlake Village, California 91361 United States

Stock Details

Ticker Symbol ARQT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001787306
CUSIP Number 03969K108
ISIN Number US03969K1088
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.